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Gene expression analysis was performed on a human renal cancer cell line (786-0) with mutated VHL gene and a transfectant with
wild-type VHL to analyse genes regulated by VHL and to compare with the gene programme regulated by hypoxia. There was a
highly significant concordance of the global gene response to hypoxia and genes suppressed by VHL. Cyclin D1 was the most highly
inducible transcript and 14-3-3 epsilon was downregulated. There were some genes regulated by VHL but not hypoxia in the renal
cell line, suggesting a VHL role independent of hypoxia. However in nonrenal cell lines they were hypoxia regulated. These included
several new pathways regulated by hypoxia, including RNase 6PL, collagen type 1 alpha 1, integrin alpha 5, ferritin light polypeptide,
JM4 protein, transgelin and L1 cell adhesion molecule. These were not found in a recent SAGE analysis of the same cell line. Hypoxia
induced downregulation of Cyclin D1 in nonrenal cells via an HIF independent pathway. The selective regulation of Cyclin D1 by
hypoxia in renal cells may therefore contribute to the tissue selectivity of VHL mutation.
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Germline mutations in the von Hippel-Lindau (VHL) tumour
suppressor gene are associated with a dominantly inherited renal
cancer syndrome (Latif et al, 1993; Chen et al, 1995) and sporadic
renal cancer. The VHL gene product pVHL is a critical component
of a multiprotein ubiquitin ligase complex that targets the
regulatory HIF-a subunits of hypoxia-inducible factor 1 (HIF-1)
for oxygen-dependent proteolysis (Iwai et al, 1999; Maxwell et al,
1999; Cockman et al, 2000; Ivan et al, 2001). HIF-1 is expressed in
response to hypoxia in most cell types and activates the
transcription of genes involved in a variety of physiological and
cellular processes including vascular endothelial growth factor
(VEGF), glucose transport (glucose transporters), glycolysis
(glycolytic enzymes), and cell survival (insulin-like growth factor
2) (Semenza, 1999). pVHL defective cells, both in cell culture and
in the context of human tumours, constitutively overexpress HIF-1
target genes irrespective of their environmental oxygen concentra-
tion (Iliopoulos et al, 1996), due to the constitutive stabilisation of
HIF-alpha subunits (Maxwell et al, 1999).
While a clear role of HIF-1 in producing vascularisation of
tumours has emerged, the role of HIF activation in oncogenesis is
still poorly defined. In particular, the mechanisms for tissue
specificity of the effects of VHL mutation are unknown. Recently,
we and others have identified a number of new pVHL target genes
and demonstrated that many of these were hypoxia-responsive in
wild-type pVHL cell lines (Koong et al, 2000; Wykoff et al, 2000;
Lal et al, 2001). Whether there are other hypoxia non-VHL
regulated pathways in renal cell lines is unknown.
Therefore in the current study, we have analysed a pair of renal
cell carcinoma transfectants that are either defective or competent
for pVHL to mRNA expression profiling. We have examined not
only the pattern of gene expression affected by pVHL status but
also that affected by hypoxia in both the absence and presence of a
functional VHL gene product The analysis shows that there was a
strong relation between genes regulated by hypoxia and those
regulated by VHL. There were no genes regulated by hypoxia
independently of VHL, but there were genes regulated by VHL that
were not hypoxia regulated in the renal cell line used for the study.
The unexpectedly high concordance prompted us to analyse
hypoxia regulation of genes in the latter class in other cell types,
and also genes from our previous study of VHL regulated genes in
a different renal cell type (Wykoff et al, 2000), which were VHL but
not hypoxia responsive. These genes were clearly regulated by
hypoxia in other nonrenal cell types.
Cyclin D1 was identified as the most highly inducible gene in the
array and in contrast to all other cell lines and studies reported,
was upregulated by hypoxia not downregulated. Additionally, 14-
3-3 epsilon was downregulated providing a combined modulation
of G1 and G2 checkpoints. The tissue selectivity of VHL
transformation in renal cancer may be related to the tissue-
specific direction of regulation of this key checkpoint by hypoxia.
MATERIALS AND METHODS
Cell lines
786-0 cells expressing pVHL or empty vector were a gift from WG
Kaelin. RCC lines were as described (Maxwell et al, 1999). RCC4/
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siVHL-HA (C1.2) and RCC4/iVA (VA1) are human renal cancer cell
lines with mutant VHL, the former transfected with an HA tagged
wild-type VHL, the latter the empty vector control. A549, EJ28,
HBL-100, and ZR-75-1 lines were from ATCC. Embryonic stem
cells with deleted HIF-1 alpha or HIF-2 alpha were generously
provided by P Carmeliet. Cells were grown in DMEM (Sigma)
supplemented with 10% foetal calf serum (Globepharm), L-
glutamine (2mM), penicillin (100mgml
 1), and streptomycin
sulphate (100Uml
 1). Studies of inducible gene expression were
performed on cells approaching confluence. Hypoxic conditions
were generated in a Napco 7001 incubator (Precision Scientific)
with 0.1% O2,5 %C O 2, and balance N2, for 16h.
Preparation and hybridisation of fluorescent labelled
cDNA
One round Eberwine’s et al (1992) RNA amplification procedure
with minor modifications was performed using polyA RNA from
786-0 RCC cancer cell line under different conditions. This
methodology is similar to that employed by Affymetrix, Inc. for
the production of probe in their chip microarray expression
analysis.
The cDNA probes were prepared from antisense RNA. Briefly,
we used 3mg of antisense RNA for Cy3 and Cy5 labelling. After
probe purification the two separated probes were combined, mixed
with hybridisation solution, denatured, and hybridised onto a
6000-feature cDNA microarray in a humidified chamber at 651C
for 16h. The slides were then rinsed by submersion and agitation
for 2min in 2 SSC with 0.1% SDS, followed by 1 SCC,
0.2 SCC, and 0.05 SCC and then dried.
Scanning and data processing
Following hybridisation, microarrays were scanned using a 10mm
resolution GenePix 4000 scanner (Axon Instruments, Inc., Foster
City, CA, USA) at variable PMT (photo-multiplier tube) voltage to
obtain maximal signal intensity with o1% probe saturation.
Resulting TIFF images for each fluorescent were analysed with
GenePix software version 3.0 (Axon Instruments, Inc., Foster City,
CA, USA). The data files generated by GenePix v3.0 were entered
into a web-based database maintained by the Bioinformatics and
Molecular Analysis Section of the CIT (Center for Information
Technology), National Cancer Institute, Bethesda, MD, USA.
To study the gene expression profiles, an average linkage
hierarchical cluster analysis utilising a correlation metric of
similarity for clustering genes was performed as described by
Eisen et al (1998). A metric multidimensional scaling for analysing
and visualising the correlation among expression profiles of
samples was also performed (Tenenbaum et al, 2000). To exclude
labelling biases, antisense RNA-based targets from either cell line
were labelled with the reciprocal fluorochrome in every other
duplicate experiment. Differentially expressed genes were desig-
nated significant if they were reproducibly induced by 42-fold in
three out of four experiments for each screening.
Ribonuclease protection assay (RPA)
Total RNA was extracted by a modified acid/guanidinium
thiocyanate/phenol/chloroform method (RNAzol B, Cinna/Biotec
Laboratories), and dissolved in hybridisation buffer (80% for-
mamide, 40mM PIPES, 400mM sodium chloride, and 1mM EDTA,
pH 8). For details of riboprobe templates employed to examine the
expression of previously described VHL-responsive genes, see
Wykoff et al (2000). Quantification of the protected species from
30mg was performed using a phosphoimager (Molecular Dy-
namics), and related to an internal control assay for the
constitutively expressed U6 small nuclear RNA (LC), performed
for each assay as described (Maxwell et al, 1999).
Cell lysis and immunoblotting
Whole-cell protein extracts were prepared from tumours by
section of frozen tissue and 30s homogenisation in denaturing
conditions as described (Wiesener et al, 1998). For Immunoblot
analysis, aliquots were separated by SDS–polyacrylamide gel
electrophoresis and transferred onto Immobilon-P membranes.
Cyclin D1 was detected using the mouse monoclonal anti-human
cyclin D1 mouse monoclonal Ab MCA1756 (Serotec, UK) (1:1000)
at 41C for 16h. HRP-conjugated goat-anti-mouse immunoglobulin
(DAKO) (1:1000) was applied for 1h at room temperature (RT).
ECL Plus (Amersham Pharmacia) was used for visualisation.
RESULTS
Comparison of VHL-responsive and hypoxia-responsive
genes on gene array
Comparing VHL-deficient 786-0 cell line expressing vector back-
bone alone (786-0) or wild-type human VHL (786-0/VHL), 28
genes were repressed and 29 genes were induced by stable
transfection of VHL (Table 1). As anticipated, some of the VHL-
repressible genes were previously identified VHL-targets, includ-
ing endothelin 1 (EDN1) and transforming growth factor alpha
(TGFA). In 786-0/VHL, 11 genes were induced and nine genes were
repressed by hypoxia (Table 2).
A striking concordance in the pattern of gene regulation across
the entire screen was observed when the VHL-responsive genes
were compared to the hypoxia-responsive genes in 786-0/VHL
(Figure 1). VHL-repressible genes (represented with reds of
various intensities in the left column) were typically hypoxia-
inducible in 786-0/VHL (red in middle column). A similar
response was seen with VHL-inducible genes, which were hypoxia
repressible (represented with greens of various intensities in the
left column).
In comparison to the changes in gene expression induced by
changes in VHL-status and hypoxia in 786-0/VHL, strikingly few
changes in gene expression were observed in 786-0 in response to
hypoxia. Three genes were significantly induced by hypoxia in 786-
0, two of which, TGFA and uridine diphosphoglucose pyropho-
sphorylase (UGP2), were also identified as hypoxia-inducible in
786-0/VHL. Array screening identified 10 genes that were
repressed by hypoxia in 786-0 (Table 3)
RNase protection analysis of candidate VHL-responsive
and hypoxia-responsive genes
RNase protection assays (RPA) were used to validate the findings.
Nine of the identified VHL-responsive genes predicted by array
screening to be either downregulated (cyclin D1 (CCND1),
ribonuclease 6 precursor (RNASE6PL), hypothetical protein
DKFZp434K1210 (HP), TGFA, cytochrome c (HCS), and cyto-
chrome P450 subfamily IIB polypeptide 6 (CYP2B)), or upregu-
lated (prostate differentiation factor (PLAB), fibronectin (FN1),
and 14-3-3 epsilon (YWHAE)) by reintroduction of VHL into 786-
0 were examined by RPA (Figure 2A(a) and (b) respectively,
comparing the paired cell lines in normoxia). Seven of these genes
were clearly confirmed to be regulated as predicted by array
screening, while one did not show regulation (HCS) and one was
not expressed at detectable levels by RPA (CYP2B).
Five of these predicted VHL-responsive genes were also
predicted by the array analysis to be regulated by hypoxia in
786-0/VHL. As illustrated in Figure 2A, each of these genes were
confirmed to be either upregulated (CCND1, RNASE6PL, HP,
TGFA) or downregulated (PLAB) by hypoxia in 786-0/VHL.
Therefore, each analysed gene predicted by array screening to be
regulated both by VHL-status and by hypoxia in 786-0/VHL was
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also regulated by VHL-status in 786-0/VHL.
VHL independent hypoxia response
To examine for the presence of VHL-independent hypoxia-
mediated changes in gene expression, seven of the hypoxia-
responsive genes predicted by array screening in 786-0 were
examined by RPA as being either upregulated (TGFA, IL6, and
UGP2) or down-regulated (HCS, CTSW, CYP2B, and NFATC4) by
hypoxia (Figure 2B(a) and (b) respectively). This included all of
the genes predicted to be significantly hypoxia-inducible in 786-0,
and four of the top five differentially expressed genes predicted to
be significantly downregulated by hypoxia in 786-0. While one of
Table 1 Candidate VHL-responsive genes in the 786-0
IMAGE Fold Reg Fold Reg
ID Abbreviation Gene VHL /VHL+ H/N
841641 CCND1 Cyclin D1 4.2 4.6
248828 ID3 Inhibitor of DNA binding 3 4 NS
756372 RARRES2 Retinoic acid receptor responder 2 4 NS
345032 RNASE6PL Ribonuclease 6 precursor 3.8 3.3
1407750 IGFBP3 Insulin-like growth factor-binding protein-3 3.6 3.3
47359 EDN1 Endothelin 1 3.4 2
726086 TFPI2 Tissue factor pathway inhibitor 2 3.4 NS
346545 LAMB1 Laminin, beta 1 3.4 NS
110467 CAV2 Caveolin 2 3.3 NS
755506 ANXA4 Annexin A4 3.2 NS
156520 TNFAIP6 Tumour necrosis factor, alpha-induced protein 6¼TSG-6 2.9 NS
272942 HP¼DKFZp434K121 Hypothetical protein dkfzp434k121 2.9 3.7
40017 HCS Cytochrome c 2.8 NS
163189 CD24 CD24 2.8 NS
272185 RPL27 Ribosomal protein L27 2.8 NS
325822 TGFA Transforming growth factor, alpha 2.6 2.8
298268 BTG1 B-cell translocation gene 1 2.6 NS
279085 MYO9B Myosin-IXB 2.6 NS
324873 ID2 Inhibitor of DNA binding 2 2.5 NS
230218 GCN5L1 General control of amino-acid synthesis (yeast) homolog-like 1 2.5 NS
83231 CYP2B Cytochrome P450, subfamily IIB, polypeptide 6 2.5 NS
855624 ALDH1 Aldehyde dehydrogenase 1 2.5 NS
343990 LOC51226 COPZ2¼nonclathrin coat protein zeta-COP 2.4 NS
725454 CKS2 Cyclin -dependent kinase regulatory subunit 2 2.3 NS
139681 NNAT Neuronatin 2.3 NS
287327 IGF1 Insulin-like growth factor 1 2.3 NS
291057 CDKN2C p18-(INK6)¼cyclin-dependent kinase 6 inhibitor 2.2 NS
364934 DAPK1 Death-associated protein kinase 1 2 NS
142788 SERPINH2 CBP2¼collagen binding protein-2¼serine protease inhibitor, clade H, 2 0.16 NS
309482 MAPK12 Mitogen activated protein (MAP) kinase 12 0.18 NS
139009 FN1 Fibronectin 0.26 NS
504763 SDC4 Syndecan-4 0.27 0.49
82734 FACL2 Fatty-acid-coenzyme A ligase, long-chain 2 0.30 0.5
491066 ACVR1 Activin A receptor, type 1¼serine/threonine protein kinase receptor R1 0.31 NS
266106 YWHAE 14-3-3 epsilon 0.32 NS
325160 NP25 Neuronal protein 25 0.33 NS
785415 LOC51763 SKIP¼skeletal muscle and kidney enriched inositol phosphatase 0.34 NS
841059 CAPG Capping protein (actin filament), gelsolin-like 0.36 NS
198904 APMCF1 APMCF1 protein 0.37 NS
489212 PDHA1 Pyruvate dehydrogenase alpha subunit 0.37 NS
825442 PTP4A2 Protein tyrosine phosphatase type IVA member 2 0.38 NS
769959 COL4A2 Collagen, type IV, alpha 2 0.38 NS
549383 PLAB Prostate differentiation factor¼MIC-1¼macrophage inhibitory cytokine-1 0.38 0.43
384078 ATP6D ATPase, H+ transporting, lysosomal (vacuolar proton pump), member D 0.38 NS
840844 HSPA5 GRP78¼78kDa glucose regulated protein precursor 0.40 NS
489453 SRM300 EST:KIAA0324 0.41 NS
588829 AARS UG5 alanyl-tRNA synthetase 0.41 NS
193913 LYN Tyrosine kinase 0.41 NS
136744 SPOP Speckle-type, poxvirus and zinc-finger domain (POZ) containing, protein 0.42 NS
897177 PGAM1 Phosphoglycerate mutase 1 (brain) 0.42 NS
324437 GRO1 MGSA¼melanoma growth stimulatory activity 0.42 NS
868304 ACTA2 Actin, alpha 2 0.43 NS
307553 KRAS2 v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog 0.45 NS
810213 IL1R1 Interleukin-1 receptor, type I 0.46 0.45
742132 ISG15 Interferon-induced 17kDa protein 0.47 NS
208161 GW128 GW128 protein 0.48 NS
325583 KIAA1538 EST:KIAA1538 0.48 NS
¼, nomenclatures represent the same gene; Fold Reg VHL /VHL+, fold-regulation of each gene by VHL-status as a ratio of expression in 786-0/expression in 786-0/VHL; Fold
Reg H/N, fold-regulation of each gene by hypoxia in 786-0/VHL as a ratio of expression in hypoxia/expression in normoxia; NS, not significantly regulated.
Concordance of VHL and hypoxia regulation of cyclin D1
CC Wykoff et al
1237
British Journal of Cancer (2004) 90(6), 1235–1243 & 2004 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sthese genes, HCS, was slightly regulated as predicted by array
screening, TGFA and IL6 were expressed but unregulated, UGP2
was too lowly expressed to make a definitive conclusion as to
regulation, and CTSW, CYP2B, and NFATC4 were not expressed at
detectable levels by RPA.
Therefore, while array screening for genes responsive to VHL-
status and hypoxia in 786-0/VHL was generally reliable, the
majority of genes predicted to be hypoxia-responsive in 786-0 were
unable to be confirmed by RPA.
Further characterisation of cyclin D1 RNA and protein
expression in renal carcinoma derived cell lines
The expression of CCND1 was examined in three additional renal
carcinoma cell lines, and its regulation by the iron chelator
desferrioxamine (DFO) (Figure 3A). CCND1 RNA was not affected
by either hypoxia or DFO in the functionally wt VHL cell line,
Caki-1. It was not modified by hypoxia in the VHL-defective cell
lines, UMRC2, UMRC3, and KTCL140 (Figure 3B). CCND1 protein
was found to be regulated by VHL-status and hypoxia in the 786-0
background similarly to the regulation of its RNA (Figure 3C).
CCND1 regulation by an inducible VHL in renal cancer cell
line RCC4
To better characterise CCND1 regulation, the effect of regulated
pVHL expression upon CCND1 protein expression was examined
in RCC4/iVHL-HA and RCC4/iVA cells the former comprising an
inducible wild-type VHL in a VHL minus background, the latter
the control. A 72h time course of DOX treatment was employed to
assess the relationship between pVHL induction and CCND1
expression (Figure 4). There was a time-dependent increase in
pVHL-HA protein expression. The kinetics of pVHL-HA expres-
sion was rapid and over a large inducible range. HIF-1a protein
expression highlighted an inverse relationship with pVHL expres-
sion (Figure 4, middle panel). In contrast to p53 expression, which
was not affected by pVHL status, the expression of the CCND1
gene product was almost completely suppressed following pVHL-
HA induction. Eliminating the possibility of nonspecific DOX-
associated side effects, CCND1 expression was not modulated in
control cells treated in parallel.
Analysis of cyclin D1 mRNA and protein expression in
nonrenal cell lines
CCND1 protein has been reported to be downregulated by hypoxia
in at least two cell lines: the pheochromocytoma derived PC12 cell
line (Conrad et al, 1999) and the ovarian carcinoma SKA cell line
(Krtolica et al, 1999). To assess the tissue specificity of responses
cell lines derived from the lung (A549), bladder (EJ-28), breast
(HBL100), or cervical (HeLa) tissue were used to analyse CCND1
regulation. CCND1 RNA was constitutively expressed and
unresponsive to hypoxia in two cell lines (A549 and EJ-28), had
very low level expression in HBL100 cells, and downregulated by
hypoxia in HeLa cells (data not shown).
CCND1 protein was downregulated by hypoxia in all the
nonrenal cell lines examined including cells derived from lung
(A549), cervical (HeLa), or breast (HBL100, ZR-75-1,T-47D)
cancers (Figure 3C).
Expression of cyclin D1 in HIFalpha mutant cells
CCND1 response to hypoxia was examined in a wild-type Chinese
hamster ovary cell line (C4.5) and a mutant derivative that is
functionally defective in HIF-1 alpha (Ka13) (Wood et al, 1998).
While CCND1 RNA was slightly downregulated by hypoxia in both
C4.5 and Ka13 (Figure 5A), its protein showed a more significant
downregulation by hypoxia, which was HIF alpha-independent
(Figure 5B). CCND1 protein response to hypoxia was examined in
wt, HIF-1 alpha knockout (
 / ), and HIF-2 alpha
 /  ES. As
illustrated in Figure 5C, CCND1 protein was downregulated by
hypoxia independent of HIF-1 alpha or HIF-2 alpha in this
background.
Expression of cyclin D1 in human renal cell carcinomas
CCND1 protein expression was examined in protein extracts from
a panel of renal cell carcinomas (RCCs) (T) of either the clear cell
Table 2 Candidate hypoxia-responsive genes in 786-0/VHL
IMAGE Fold Reg Fold Reg
ID Abbreviation Gene H/N VHL /VHL+
841641 CCND1 Cyclin D1 4.6 4.2
712341 RNASE6PL Ribonuclease 6 precursor 3.3 3.8
272942 HP¼DKFZp434K121 Hypothetical protein DKFZp434K121 3.7 2.9
1407750 IGFBP3 Insulin-like growth factor-binding protein-3 3.3 3.6
504527 DUSP1 CL100¼MAP kinase phosphatase 1 3.2 NS
325822 TGFA Transforming growth factor, alpha 2.8 2.6
51817 MFNG Manic fringe (Drosophila) homolog 2.4 NS
460538 GSR Glutathione reductase 2.1 NS
755578 SLC7A5 Solute carrier family 7 (cationic amino-acid transporter), member 5 2.1 NS
486436 UGP2 Uridine diphosphoglucose pyrophosphorylase 2.1 NS
47359 EDN1 Endothelin 1 2 3.4
549383 PLAB Prostate differentiation factor¼MIC-1¼macrophage inhibitory cytokine-1 0.43 0.38
810213 IL1R1 Interleukin-1 receptor, type I 0.45 0.46
756092 HLA-DQA1 Major histocompatibility complex (MHC) class II, DQ alpha 1 chain 0.45 NS
307325 EDG1 Endothelial differentiation protein¼putative G-protein-coupled receptor 0.46 NS
724397 CTSW Lymphopain¼C1 peptidase expressed in natural killer and cytotoxic T cells 0.49 NS
171693 D6S49E LST1¼leukocyte-specific transcript-1¼interferon-gamma-inducible gene 0.49 NS
504763 SDC4 Syndecan-4 0.49 0.27
181998 NFATC4 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 0.50 NS
82734 FACL2 Fatty-acid-Coenzyme A ligase, long-chain 2 0.50 0.3
¼, nomenclatures represent the same gene; Fold Reg VHL /VHL+, fold-regulation of each gene by VHL-status as a ratio of expression in 786-0/expression in 786-0/VHL; Fold
Reg H/N, fold-regulation of each gene by hypoxia in 7860/VHL as a ratio of expression in hypoxia/expression in normoxia; NS, not significantly regulated.
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s(CC-RCC) or papillary type and compared to CCND1 protein
expression in adjacent macroscopically normal tissue (N) from the
same patient. In contrast to the four papillary tumours, nine of 10
CC-RCCs expressed markedly elevated levels of CCND1 protein
(data not shown).
Regulation of other genes by VHL but not hypoxia
There were more genes regulated by VHL re-expression than
regulated by hypoxia in the array. As the experiment with
inducible VHL showed a wide range of expression with time and
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Figure 1 Hierarchical cluster analysis of differentially expressed genes.
Each row represents a single gene (identified by its abbreviation at the right.
See Table 1, 2, or 3 for corresponding gene name). Each column represents
the average of the four replicates for each experiment. VHL /þ,
comparison of gene expression in 768-0 ( ) vs 786-0/VHL (þ)i n
normoxia; 786-0/VHL H/N, comparison of gene expression in hypoxia (H)
vs normoxia (N) in 786-0/VHL; 786-0 H/N, comparison of gene expression
in hypoxia (H) vs normoxia (N) in 786-0. Significantly regulated genes are
represented by a block of a particular colour, which was determined by its
sign and magnitude of regulation by the given stimulus; red blocks indicate
overexpressed genes while green blocks indicate underexpressed genes.
Black bars indicate genes with approximately equivalent expression levels
and grey bars indicate missing data. Colour code at bottom correlates
colour intensity with fold-regulation. Dendrogram at the left of the figure
illustrates the relationship between the observed patterns of gene
regulation, where the shorter the branch length between two gene, the
more similar their pattern of regulation across the three comparisons.
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Figure 2 RPAs of array screening predicted VHL and hypoxia-
responsive target genes. Cells were exposed to either normoxia (N; 20%
O2) or hypoxia (H; 0.1% O2) for 16h. Analysis of expression in 786-0 and
the corresponding wt VHL stable tranfectant (þVHL) by RPA. See Table
1–3 for corresponding gene names and a summary of the illustrated RPAs.
(A) Genes predicted to be either downregulated (a) or upregulated (b) by
wt VHL. (c) Expression of control genes: GLUT-1, a known hypoxia-
inducible VHL target; LC, internal control assay (constitutively expressed
U6 small nuclear RNA). All samples and assays (in A and B) were
controlled in both ways. (B) Genes predicted to be either upregulated (a)
or downregulated (b) by hypoxia in 786-0.
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sa similar reciprocal regulation of CCND1, it is possible that a
transfectant with a set high level of VHL could be sufficient to
continue to repress some genes in hypoxia. The nonrenal cell lines
were therefore analysed for hypoxic regulation of genes that
showed weak regulation in the transfectant. FN1 was hypoxia-
inducible in both (A549, HBL100) nonrenal cell lines in which its
RNA was detected.
Of importance in interpreting these results, a similar phenom-
enon was observed in our previous study of VHL-responsive genes
in the RCC4 background. In view of the results here we reanalysed
six of these genes (collagen type 1alpha 1, integrin alpha 5, ferritin
light polypeptide, JM4 protein, transgelin, L1 cell adhesion
molecule) in the nonrenal cell lines here and they were all
hypoxia-responsive in at least one of them (Figure 6).
However, another observation in the renal cell lines was that
VHL expression had opposite effects in the 786-0 and the RCC4 on
certain genes. Restoration of VHL suppressed LICAM and
transgelin in the RCC4 cells but induced expression in the 786-0
cells. Thus hypoxia regulation in opposite directions can occur in
different cell lines, again reflecting cell type specific operation of
hypoxia pathways.
Table 3 Candidate hypoxia-responsive genes in 786-0
IMAGE Fold Reg
ID Abbreviation Gene H/N
486436 UGP2 Uridine diphosphoglucose pyrophosphorylase 3.4
310406 IL6 Interleukin-6 2.3
325822 TGFA Transforming growth factor, alpha 2.2
724397 CTSW Lymphopain¼C1 peptidase expressed in natural killer and cytotoxic T cells 0.40
40017 HCS Cytochrome c 0.42
83231 CYP2B Cytochrome P450, subfamily IIB, polypeptide 6 0.43
262053 E2IG3 Putative nucleotide binding protein, oestradiol-induced 0.43
181998 NFATC4 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 0.46
182264 SELP P-selectin¼CD62¼GMP140¼granulocyte membrane protein 140 0.48
788518 PXMP3 Peroxisomal membrane protein 3 (35kDa, Zellweger syndrome) 0.48
43630 AKAP10 Kinase A anchor protein 10 0.48
1071934 MAP3K12 Mitogen-activated protein kinase kinase kinase 12 0.49
359021 CHD3 Zinc-finger helicase (hZFH) 0.50
¼, nomenclatures represent the same gene. Fold Reg H/N, fold-regulation of each gene by hypoxia in 786-0 as a ratio of expression in hypoxia/expression in normoxia.
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Figure 3 Further characterisation of the cyclin D1 response to hypoxia.
Cells were exposed to either normoxia (N; 20% O2), hypoxia (H; 0.1%
O2), or desferrioxamine (DFO; 100mM) for 16h. (A) RPAs of cyclin D1
(CCND1) and GLUT-1 in either 786-0 or 786-0/VHL exposed to either N,
H, or DFO. (B) RPAs of CCND1 in Caki-1 (pVHL functionally wt),
UMRC2, UMRC3, and KTCL140 (pVHL functionally deficient). LC, internal
control assay (constitutively expressed U6 small nuclear RNA). (C)
Western blots of whole-cell extracts using anti-human CCND1 mono-
clonal Ab MCA1756; CCND1 protein expression in kidney (786-0, 786-0/
VHL), lung (A549), cervical (HeLa), and breast (HBL100, ZR-75-1, T-47D)
derived cell lines. Numbers to the right of protein gels indicate approximate
molecular weights (kDa) as determined by protein standards run on each
gel.
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Figure 4 Time course of DOX-inducible pVHL-HA protein expression
and effect upon downstream targets. Parallel cultures of RCC4/iVHL-HA
(C1.2) and RCC4/iVA (VA1) were grown in the presence of DOX
(0.5mgml
 1) for up to 72h. Whole-cell protein extracts were collected
subconfluent populations of C1.2 and VA1 cells at 3-h intervals for the first
24h, and daily thereafter. Whole-cell extracts (20mg) were resolved by
SDS–PAGE: VHL-HA (13.5%); HIF-1a (6%); and cyclin D1/p53 (10%) and
immunoblotted with: anti-HA (rat mono); anti-HIF-1a (mAb clone 54);
anti-cyclin D1 (pAb MCA1756); and anti-p53 (mAb DO-7). Equivalent
loading was confirmed by Coomassie staining membrane after immuno-
blotting.
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This study has provided insight into the role of VHL in the global
response to hypoxia. Specifically, at least in the 786-0 background,
VHL plays a central and dominant role in eliciting the changes in
gene expression generated by hypoxia. In contrast, there was no
further consistent gene regulation in response to hypoxia in the
absence of a functional VHL gene product.
These results should be compared to the recent SAGE analysis of
the same renal cell lines (Jiang et al, 2003). These authors found 38
genes induced by hypoxia in the 786-0/VHL cell in common with
those downregulated by re-expression of VHL in 786-0 cells. It is of
interest that not one of the genes we found to be regulated in
common by the gene array and validated by RNase protection is in
that list and our list contains genes previously validated in other
studies on renal cancer. This emphasises the importance of
different methodologies in analysing gene expression. Some of the
differences could be due to different cut points of analysis as well
as inherent methodology differences, for example in sequencing
and hybridisation.
A novel observation was that a large proportion of genes from
our array experiments were significantly regulated by VHL-status
but insignificantly regulated by hypoxia in VHL transfectants,
while hypoxia-responsive in nonrenal cell lines. One potential
factor contributing to this observation is that stable over-
expression of exogenous pVHL to a level in excess to that which
had previously been present in the precursor cells of the cancer
may have an inhibitory effect on some hypoxia-mediated changes
in gene expression. Another is that these genes belong to hypoxia
pathways that have become modified during progressive develop-
ment of renal cancer and are no longer responsive. An interesting
possibility is that they represent a VHL pathway independent of
HIF. Jiang et al (2003) found many more genes by SAGE that were
VHL regulated but not hypoxia responsive but they did not test
whether they were hypoxia inducible in other cell types.
Other genes we identified as hypoxia regulated in nonrenal cell
lines have roles that could contribute to the malignant phenotype,
including cell adhesion and VEGF presentation, L1CAM (Castella-
ni et al, 2002), iron metabolism or gelling of the actin cytoskeleton,
transgelin.
The genes identified from the current analyses broaden the
spectrum of VHL and hypoxia-responsive target genes to include
many that have functions of interest to cancer biology. Tumour
growth factor alpha, found to be upregulated by VHL mutation
and hypoxia in this screen, has recently been shown to have a key
role in growth of renal cancers. 14-3-3-epsilon, a cell cycle
inhibitor that complexes with cdc2 kinase (van Hemert et al, 2001)
was downregulated by VHL mutation and provides a suppression
of a second cell cycle checkpoint that would synergise with cyclin
D1 changes.
The gene most upregulated by hypoxia and VHL mutation was
cyclin D1. Over the past decade, the expression of CCND1 has
emerged as being clearly disregulated in a variety of human
neoplasms and having a major role in tumorigenesis. Recently
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Figure 5 Response of cyclin D1 to hypoxia is HIF-1a and HIF-2a
independent in non-RCC cells. Cells were exposed to either normoxia (N;
20% O2) or hypoxia (H in non-RCC cells; 0.1% O2) for 16h unless
otherwise stated. (A and B) Examination of wild-type CHO cells (C4.5)
and HIF-1a deficient CHO cells (Ka13). (A) RPAs of GLUT-1 and cyclin D1
(CCND1). LC, internal control assay (constitutively expressed U6 small
nuclear RNA). (B and C) Western blots of whole-cell extracts using either
anti-human HIF-1a mouse monoclonal Ab NB 100-105 or anti-human
CCND1 monoclonal Ab MCA1756. (B) HIF-1a and CCND1 protein
expression. (C) Induction of CCND1 protein by hypoxia (1% O2,1 6h )i n
mouse wt (þ/þ), HIF-1a knockout (1a / ) and HIF-2a knockout (2a /
 ) embryonic stem cells. Numbers to the right of protein gels indicate
approximate molecular weights (kDa) as determined by protein standards
run on each gel.
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Figure 6 Comparison of the hypoxic regulation of genes modulated by
VHL in renal cell lines with their regulation in nonrenal cell lines. COL1A1
collagen type 1, alpha 1, ITGA5 integrin, alpha 5,— FTL ferritin, light
polypeptide, JM4 JM4 protein, TAGLN transgelin, L1CAM L1 cell adhesion
molecule; FN1, fibronectin; LC, loading control.
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in the same cell line and found hypoxia upregulation of CCND1
and maintenance of CCND1 at confluence, which was not related
to protein stabilisation. Similarly to their study, this only occurred
in cell lines that had lost VHL function and been transfected with
VHL (Bindra et al, 2002). In contrast, Maher’s group used an array
of 558 genes and found CCND1 upregulated in a VHL mutant renal
cancer cell line (RCC4), but it was not regulated by hypoxia
(Zatyka et al, 2002). This may be due to the problem discussed
above where transfection may not restore hypoxia inducibilty of
genes in such cells. Our results in that cell line with an inducible
VHL clearly show that VHL upregulation produces suppression of
CCND1, emphasing the importance of trying to titrate the level of a
suppressor gene to determine the effects.
CCND1 protein was downregulated by hypoxia in multiple
nonrenal cell lines as previously reported (Conrad et al, 1999;
Krtolica et al, 1999), and we show here that this is by an HIF-alpha
independent mechanism as shown in two different mutant cell
types for HIF1-alpha and one for HIF2-alpha. The mechanism
varied in the nonrenal cell lines, for example, in A549 cells the
RNA was not hypoxia-responsive in while its protein was down-
regulated, whereas in HeLa cells both were downregulated. Taken
together, these results indicate that the controls responsible for
modulating the CCND1 response to hypoxia are complex and cell
type specific. Nevertheless, the renal cell lines stand out as
consistently maintaining CCND1 expression under hypoxia in
contrast to all other types examined here and reported in the
literature. Our findings are in agreement with clinical data that
approximately 75% of RCCs expressed a higher level of CCND1
protein than the normal kidney cortex (Lin et al, 1998; Aaltomaa
et al, 1999; Hedberg et al, 1999; Stassar et al, 2001).
The renal specificity of transformation by VHL could be partly
determined by the signalling pathway we describe here. The
mechanism of CCND1 regulation will require further analysis, but
a possibility is indirect regulation via TGF alpha or other growth
factors regulated by HIF. Differential tissue specific regulation of
genes by hypoxia provides a putative reason, for the remarkable
specificity of VHL to produce invasive renal tumours. Our work
shows three contributing factors – the upregulation of CCND1 in
the presence of VHL mutation, downregulation of 14-3-3 epsilon,
and lack of an HIF independent hypoxia response that could
mediate the suppression of CCND1, as in other cell types. The
global gene array has shown that essentially all hypoxia-regulated
genes are regulated by VHL in renal cancer contributing to an
understanding of tissue selectivity of transformation.
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